Encontrados 2 documentos, a visualizar página 1 de 1
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort
Casco, N; Jorge, AL; Palmero, DJ; Alffenaar, JW; Fox, GJ; Ezz, W; Cho, JG; Denholm, J; Skrahina, A; Solodovnikova, V; Arbex, MA; Alves, T; Rabahi, MFBackground Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19. Methods We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end...
New and repurposed drugs to treat multidrug- and extensively drug-resistant tub...
Silva, DR; Dalcolmo, M; Tiberi, S; Arbex, MA; Munoz-Torrico, M; Duarte, R; D'Ambrosio, L; Visca, D; Rendon, A; Gaga, M; Zumla, A; Migliori, GBMultidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. ...